03320.HK
China Resources Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 4.44
+0.57%Year over year
Reported trailing growth
- Revenue
- +8.8%
- EBITDA
- +3.9%
- EBIT
- +11.7%
- EPS
- -5.4%
- Free cash flow
- -19.7%
- Operating cash flow
- -22.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.4%
- EBITDA
- +9.2%
- EBIT
- +13.6%
- Net income
- +7.3%
- EPS
- +9.4%
- Free cash flow
- +41.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026